Ambry Genetics and SoftGenetics Form Alliance for Extended Bioinformatics Support for Sequencing Projects
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Ambry Genetics and SoftGenetics have announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics’ NextGENe software for next-generation sequencing projects performed at Ambry.
Anja Kammesheidt PhD, Ambry’s CSO said, “Our team at Ambry has been providing genomics solutions on Illumina’s® Genome Analyzer platform for 2 years now. In light of diversifying applications, increasing project sizes, and new genomes to be explored, having a proven and innovative partner for bioinformatics is key. While some of our clients are interested in performing their own analyses, others are asking for extended support. We have been impressed with SoftGenetics’ software tools, as well as their approach to take care of the clients’ needs which is very much in line with Ambry’s philosophy. We are looking forward to working together to provide tailored services to our clients.”
Jonathan Liu PhD, SoftGenetics VP Research and Development echoed Dr. Kammesheidt’s thoughts and added that “the SoftGenetics/Ambry partnership provides a new strategic alliance that will not only provide a single streamlined source for next-generation sequencing researchers but will also provide SoftGenetics with a deepened vision of future researcher requirements, allowing NextGENe to remain at the forefront of next-generation sequencing software.”
“This highly unique alliance” , continued John Fosnacht, SoftGenetics VP Sales and Marketing, “provides researchers wishing to utilize the power of next-generation sequencing a distinctive value proposition by combining the technical quality of Ambry Genetics sequencing with the unique analysis capabilities of NextGENe without the heavy investment typically required in next-generation sequencing instrumentation and bioinformatics. We all believe this is a true win-win situation for everyone.”
Anja Kammesheidt PhD, Ambry’s CSO said, “Our team at Ambry has been providing genomics solutions on Illumina’s® Genome Analyzer platform for 2 years now. In light of diversifying applications, increasing project sizes, and new genomes to be explored, having a proven and innovative partner for bioinformatics is key. While some of our clients are interested in performing their own analyses, others are asking for extended support. We have been impressed with SoftGenetics’ software tools, as well as their approach to take care of the clients’ needs which is very much in line with Ambry’s philosophy. We are looking forward to working together to provide tailored services to our clients.”
Jonathan Liu PhD, SoftGenetics VP Research and Development echoed Dr. Kammesheidt’s thoughts and added that “the SoftGenetics/Ambry partnership provides a new strategic alliance that will not only provide a single streamlined source for next-generation sequencing researchers but will also provide SoftGenetics with a deepened vision of future researcher requirements, allowing NextGENe to remain at the forefront of next-generation sequencing software.”
“This highly unique alliance” , continued John Fosnacht, SoftGenetics VP Sales and Marketing, “provides researchers wishing to utilize the power of next-generation sequencing a distinctive value proposition by combining the technical quality of Ambry Genetics sequencing with the unique analysis capabilities of NextGENe without the heavy investment typically required in next-generation sequencing instrumentation and bioinformatics. We all believe this is a true win-win situation for everyone.”
